Billionaire Lei Zhang’s 10 Stock Picks with Huge Upside Potential

2. BeiGene, Ltd. (NASDAQ:ONC)

Hillhouse Capital’s stake: $702,711,832

Upside Potential: 43.9%

Number of Hedge Fund Holders: 30

BeiGene, Ltd. (NASDAQ:ONC) is a global oncology company dedicated to developing innovative, affordable cancer treatments. With a robust pipeline and a growing commercial portfolio, it focuses on hematology and solid tumors. Its lead product, BRUKINSA®, a best-in-class BTK inhibitor, is approved in over 70 markets. BeiGene integrates research, development, and manufacturing in-house, enabling faster, cost-effective drug development and positioning it as a leader in the evolving oncology landscape.

In Q1 2025, BeiGene reported $1.1 billion in total revenue, a 49% increase from Q1 2024, driven by strong global sales of BRUKINSA ($792M, +62%) and TEVIMBRA ($171M, +18%). The company achieved positive GAAP operating profit and net income for the first time, with a $272 million improvement year-over-year. Operating expenses rose 6%, while gross margin improved to 85%. BeiGene also delivered its third consecutive quarter of positive operating cash flow, improving by $353 million year-over-year.

BeiGene reported strong Q1 2025 results with $136 million in non-GAAP net income and maintained full-year guidance of $4.9–$5.3 billion in revenue. The company is enhancing supply chain resiliency through global manufacturing investments, including its US-based Hopewell, NJ facility. It’s progressing key programs like BRUKINSA and TEVIMBRA, advancing multiple Phase II/III trials, and planning a pivotal head-to-head study for its BTK degrader. BeiGene also aims for GAAP breakeven and positive cash flow in 2025, despite tariff uncertainties.